This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MacGillivray, M. H.
Right arrow Articles by Conboy, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacGillivray, M. H.
Right arrow Articles by Conboy, T. A.
Related Collections
Right arrow Endocrinology

PEDIATRICS Vol. 102 No. 2 Supplement August 1998, pp. 527-530

Current Dosing of Growth Hormone in Children With Growth Hormone Deficiency: How Physiologic?

Received Feb 6, 1998; accepted Mar 20, 1998.

Margaret H. MacGillivray*, Sandra L. BlethenDagger , John G. Buchlis*, Richard R. Clopper*, David E. Sandberg*, and Thomas A. Conboy*

From the * Department of Pediatrics, State University of New York at Buffalo, and Children's Hospital of Buffalo, Buffalo, New York; and Dagger  Genentech Inc, South San Francisco, California.

The current doses of recombinant growth hormone (rGH) are two to three times those used in the pituitary growth hormone era. These rGH doses (0.025 to 0.043 mg/kg/d) are similar to or moderately greater than the physiologic requirements. Growth velocity and height gains have been shown to be greater with 0.05 mg/kg/d of rGH than with 0.025 mg/kg/d. Larger doses of GH and early initiation of treatment result in greater heights at the onset of puberty and greater adult heights. Earlier onset of puberty and more rapid maturation, as indicated by bone age, were not observed in children who were given 0.18 to 0.3 mg/kg/wk of rGH. The frequency of adverse events is very low, but diligent surveillance of all children who are treated with rGH is essential.

Key words: growth hormone dose, height outcomes, bone age, onset of puberty.




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
D. S. Hardin, S. F. Kemp, and D. B. Allen
Twenty Years of Recombinant Human Growth Hormone in Children: Relevance to Pediatric Care Providers
Clinical Pediatrics, May 1, 2007; 46(4): 279 - 286.
[Abstract] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
B. S. Finkelstein, T. F. Imperiale, T. Speroff, U. Marrero, D. J. Radcliffe, and L. Cuttler
Effect of Growth Hormone Therapy on Height in Children With Idiopathic Short Stature: A Meta-analysis
Arch Pediatr Adolesc Med, March 1, 2002; 156(3): 230 - 240.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet
Optimizing GH Therapy in Adults and Children
Endocr. Rev., August 1, 2001; 22(4): 425 - 450.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. O. Reiter, S. L. Blethen, J. Baptista, and L. Price
Early Initiation of Growth Hormone Treatment Allows Age-Appropriate Estrogen Use in Turner's Syndrome
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1936 - 1941.
[Abstract] [Full Text]

Home page
 PediatricsHome page
M. P. Wajnrajch, J. M. Gertner, Z. Huma, J. Popovic, K. Lin, P. C. Verlander, S. D. Batish, P. F. Giampietro, J. G. Davis, M. I. New, et al.
Evaluation of Growth and Hormonal Status in Patients Referred to the International Fanconi Anemia Registry
Pediatrics, April 1, 2001; 107(4): 744 - 754.
[Abstract] [Full Text] [PDF]